Myopathic rheumatic diseases (polymyositis, dermatomyositis, inclusion body myositis)

12S138: Meet the Panel: Challenging Cases in Adult and Juvenile Myositis

Panelist(s)

• CO

  Chester Oddis, MD

  University of Pittsburgh
  Pittsburgh, PA, United States

  Disclosure(s): Boehringer-Ingelheim: Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); EMD Serono: Grant/Research Support (Ongoing); Novartis: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing)
• LR

  Lisa Rider, MD

  NIEHS, NIH
  Garrett Park, MD, United States

  Disclosure(s): AstraZeneca: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, December 31, 2021); Hope Pharmaceuticals: Grant/Research Support (Ongoing)
• SS

  Susan Shenoi, MS, MBBS, RhMSUS

  Seattle Childrens Hospital
  Mercer Island, WA, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose
• VW

  Victoria Werth, MD

  University of Pennsylvania
  Wynnewood, PA, United States

  Disclosure(s): AbbVie: Consultant (Terminated, March 17, 2022); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Anaptysbio: Consultant (Ongoing); Argenx: Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol Myers Squibb: Consultant (Ongoing); Celgene: Consultant (Terminated, October 21, 2021), Grant/Research Support (Terminated, October 21, 2021); Corbus: Grant/Research Support (Terminated, January 11, 2021); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); Galderma: Consultant (Ongoing); Genentech: Grant/Research Support (Ongoing); Gilead: Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Horizon Therapeutics: Grant/Research Support (Ongoing); Idera: Consultant (Ongoing); Incyte: Consultant (Ongoing); Janssen: Consultant (Ongoing); Kyowa Kirin: Consultant (Ongoing); Lilly: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Nektar: Consultant (Ongoing); Novartis: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Principia: Consultant (Ongoing); Regeneron: Grant/Research Support (Ongoing); Resolve: Consultant (Ongoing), Consultant (Ongoing); Rome Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); Ventus: Grant/Research Support (Ongoing); Viela: Consultant (Terminated, May 6, 2022), Grant/Research Support (Terminated, May 6, 2022); Xencor: Consultant (Ongoing)

This session will include an expert panel to discuss the diagnosis and management of challenging cases in juvenile and adult myositis. This session will also highlight international perspectives and include a discussion on the future therapeutic landscape of myositis.

Presentations:

• 2:00 PM – 2:45 PM PT

  Meet the Panel: Challenging Cases in Adult and Juvenile Myositis
  

  Panelist: Chester Oddis, MD – University of Pittsburgh

  Panelist: Lisa Rider, MD – NIEHS, NIH

  Panelist: Susan Shenoi, MS, MBBS, RhMSUS – Seattle Childrens Hospital

  Panelist: Victoria Werth, MD – University of Pennsylvania
• 2:45 PM – 3:00 PM PT

  Q&A